Novo Nordisk A/S (NVO) Stock
Novo Nordisk A/S stock price chart
NVO stock quote & key statistics
Novo Nordisk A/S annual financials
Income statement →| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $309.06B | $102.43B | $19.55 |
| FY2024 | $290.40B | $100.99B | $13.95 |
| FY2023 | $232.26B | $83.68B | $2.74 |
| FY2022 | $176.95B | $55.52B | $1.73 |
| FY2021 | $140.80B | $47.76B | $1.64 |
Fiscal year ending December 31. Source: company filings via EODHD.
About Novo Nordisk A/S
Novo Nordisk A/S is a prominent healthcare company renowned for its global leadership in pharmaceutical research, development, manufacturing, and marketing. Operating worldwide, the company focuses on two primary segments: Diabetes and Obesity care, and Biopharm. In the Diabetes and Obesity care segment, Novo Nordisk delivers a comprehensive range of products encompassing insulins, GLP-1 analogs, and related delivery systems, as well as oral antidiabetic medications. The segment also addresses obesity and other chronic diseases, aiming to provide effective therapies that improve patient outcomes and quality of life.
Within its Biopharmaceuticals segment, Novo Nordisk offers therapeutic solutions in specialized areas such as haemophilia, growth disorders, and hormone replacement therapy. This segment underscores the company's commitment to advancing treatments that address critical medical needs across diverse patient populations. Additionally, Novo Nordisk maintains strategic collaborations with industry leaders like Gilead Sciences, Inc., and engages in research partnerships, such as its collaboration with Lumen Bioscience, Inc., focusing on oral biologics for cardiometabolic diseases.
Founded in 1923 and headquartered in Bagsværd, Denmark, Novo Nordisk has established itself as a cornerstone of innovation and excellence in healthcare. With a rich history of pioneering medical advancements and a steadfast commitment to research and development, the company continues to shape the future of healthcare through its dedication to improving the lives of millions worldwide. By leveraging its expertise and global reach, Novo Nordisk remains at the forefront of pharmaceutical innovation, driving forward transformative therapies that address unmet medical needs and deliver sustainable value to patients and healthcare systems alike.
Novo Nordisk A/S stock FAQ
What is the Novo Nordisk A/S stock ticker symbol?
Novo Nordisk A/S trades on the NYSE under the ticker symbol NVO.
What sector and industry is Novo Nordisk A/S in?
Novo Nordisk A/S is classified in the Healthcare sector, Drug Manufacturers - General industry.
How many employees does Novo Nordisk A/S have?
Novo Nordisk A/S has about 66,700 full-time employees.
What were Novo Nordisk A/S's revenue and earnings last fiscal year?
Novo Nordisk A/S reported revenue of $309.06B and net income of $102.43B in fiscal 2025, with earnings per share of $19.55. Revenue grew 6.4% from the prior year.
When did Novo Nordisk A/S go public?
Novo Nordisk A/S stock began trading on January 4, 1982.